Generalized Anxiety Disorder - Pipeline Insight, 2025
Description
DelveInsight’s, “Generalized Anxiety Disorder - Pipeline Insight, 2025” report provides comprehensive insights about 12+ companies and 15+ pipeline drugs in Generalized Anxiety Disorder pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Generalized Anxiety Disorder: Overview
Generalized Anxiety Disorder (GAD) is a common and often debilitating mental health condition characterized by excessive, uncontrollable worry about a wide range of topics, such as work, health, finances, and social interactions, lasting for six months or more. Unlike occasional worry, GAD involves persistent anxiety that significantly interferes with daily functioning. Individuals with GAD experience physical and psychological symptoms, including restlessness, fatigue, irritability, difficulty concentrating, muscle tension, and sleep disturbances. These symptoms can make it difficult to perform routine tasks, engage in social situations, and meet responsibilities. GAD is often underdiagnosed and undertreated, partly due to its subtle onset and symptom overlap with conditions like depression. It also increases the risk of other health issues, such as depression, suicidal ideation, and cardiovascular events. Primary care physicians play an essential role in diagnosing and managing GAD, with treatment typically involving Cognitive Behavioral Therapy (CBT) and medications like SSRIs and SNRIs to regulate serotonin and norepinephrine levels in the brain.
Generalized Anxiety Disorder (GAD) is a mental health condition marked by persistent and excessive worry about a wide range of everyday issues, often without a clear or realistic cause. This anxiety can significantly impair a person's ability to function in daily life, impacting areas such as work, relationships, and overall well-being. People with GAD often find themselves constantly worrying about events such as work deadlines, social interactions, health, finances, and family matters, even when no immediate threat or danger exists. This worry can become so overwhelming that it interferes with their ability to focus on tasks, make decisions, or enjoy leisure activities. Despite recognizing that their worries are irrational or exaggerated, individuals with GAD have difficulty controlling or stopping these thoughts, which only intensifies the anxiety. Restlessness and irritability are common, and even minor issues can feel intolerable, which may lead to emotional instability and strain relationships. GAD can also cause concentration problems, making it hard to focus on important tasks or remember things, which can result in missed deadlines or mistakes at work or home. In addition to the emotional and mental symptoms, GAD also brings a range of physical symptoms due to the body's constant state of heightened alertness. These may include muscle tension, particularly in the neck, shoulders, and jaw, which can lead to discomfort or tension headaches.
Diagnosing Generalized Anxiety Disorder (GAD) involves a detailed evaluation based on criteria from the DSM-5 and ICD-10, ensuring correct symptom identification, severity assessment, and exclusion of other causes. Core symptoms include excessive, uncontrollable worry lasting more than six months, along with at least three additional symptoms such as restlessness, fatigue, muscle tension, irritability, and difficulty concentrating, all of which impair daily functioning. The diagnosis also requires ruling out other conditions like panic disorder, obsessive-compulsive disorder, or medical issues like hyperthyroidism. A thorough clinical interview, along with tools like the GAD-7 scale, helps assess symptom severity, while differential diagnosis ensures the correct identification of GAD.
The treatment for Generalized Anxiety Disorder (GAD) typically involves a combination of psychotherapy, medication, and lifestyle changes aimed at reducing symptoms and improving overall well-being. Cognitive Behavioral Therapy (CBT) is the most effective psychotherapy for GAD, focusing on identifying and challenging negative thought patterns and behaviors. It helps individuals develop healthier coping mechanisms through techniques like cognitive restructuring and exposure therapy. Acceptance and Commitment Therapy (ACT) is another approach that encourages acceptance of anxiety, helping individuals live according to their values despite the presence of anxiety. Medications, such as antidepressants and anxiolytics, are often used to regulate mood and alleviate anxiety, especially when symptoms are severe or persistent.
""Generalized Anxiety Disorder- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Generalized Anxiety Disorder pipeline landscape is provided which includes the disease overview and Generalized Anxiety Disorder treatment guidelines. The assessment part of the report embraces, in depth Generalized Anxiety Disorder commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Generalized Anxiety Disorder collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Generalized Anxiety Disorder report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Generalized Anxiety Disorder Emerging Drugs
Further product details are provided in the report……..
Generalized Anxiety Disorder: Therapeutic Assessment
This segment of the report provides insights about the different Generalized Anxiety Disorder drugs segregated based on following parameters that define the scope of the report, such as:
Generalized Anxiety Disorder: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Generalized Anxiety Disorder therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Generalized Anxiety Disorder drugs.
Generalized Anxiety Disorder Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Generalized Anxiety Disorder: Overview
Generalized Anxiety Disorder (GAD) is a common and often debilitating mental health condition characterized by excessive, uncontrollable worry about a wide range of topics, such as work, health, finances, and social interactions, lasting for six months or more. Unlike occasional worry, GAD involves persistent anxiety that significantly interferes with daily functioning. Individuals with GAD experience physical and psychological symptoms, including restlessness, fatigue, irritability, difficulty concentrating, muscle tension, and sleep disturbances. These symptoms can make it difficult to perform routine tasks, engage in social situations, and meet responsibilities. GAD is often underdiagnosed and undertreated, partly due to its subtle onset and symptom overlap with conditions like depression. It also increases the risk of other health issues, such as depression, suicidal ideation, and cardiovascular events. Primary care physicians play an essential role in diagnosing and managing GAD, with treatment typically involving Cognitive Behavioral Therapy (CBT) and medications like SSRIs and SNRIs to regulate serotonin and norepinephrine levels in the brain.
Generalized Anxiety Disorder (GAD) is a mental health condition marked by persistent and excessive worry about a wide range of everyday issues, often without a clear or realistic cause. This anxiety can significantly impair a person's ability to function in daily life, impacting areas such as work, relationships, and overall well-being. People with GAD often find themselves constantly worrying about events such as work deadlines, social interactions, health, finances, and family matters, even when no immediate threat or danger exists. This worry can become so overwhelming that it interferes with their ability to focus on tasks, make decisions, or enjoy leisure activities. Despite recognizing that their worries are irrational or exaggerated, individuals with GAD have difficulty controlling or stopping these thoughts, which only intensifies the anxiety. Restlessness and irritability are common, and even minor issues can feel intolerable, which may lead to emotional instability and strain relationships. GAD can also cause concentration problems, making it hard to focus on important tasks or remember things, which can result in missed deadlines or mistakes at work or home. In addition to the emotional and mental symptoms, GAD also brings a range of physical symptoms due to the body's constant state of heightened alertness. These may include muscle tension, particularly in the neck, shoulders, and jaw, which can lead to discomfort or tension headaches.
Diagnosing Generalized Anxiety Disorder (GAD) involves a detailed evaluation based on criteria from the DSM-5 and ICD-10, ensuring correct symptom identification, severity assessment, and exclusion of other causes. Core symptoms include excessive, uncontrollable worry lasting more than six months, along with at least three additional symptoms such as restlessness, fatigue, muscle tension, irritability, and difficulty concentrating, all of which impair daily functioning. The diagnosis also requires ruling out other conditions like panic disorder, obsessive-compulsive disorder, or medical issues like hyperthyroidism. A thorough clinical interview, along with tools like the GAD-7 scale, helps assess symptom severity, while differential diagnosis ensures the correct identification of GAD.
The treatment for Generalized Anxiety Disorder (GAD) typically involves a combination of psychotherapy, medication, and lifestyle changes aimed at reducing symptoms and improving overall well-being. Cognitive Behavioral Therapy (CBT) is the most effective psychotherapy for GAD, focusing on identifying and challenging negative thought patterns and behaviors. It helps individuals develop healthier coping mechanisms through techniques like cognitive restructuring and exposure therapy. Acceptance and Commitment Therapy (ACT) is another approach that encourages acceptance of anxiety, helping individuals live according to their values despite the presence of anxiety. Medications, such as antidepressants and anxiolytics, are often used to regulate mood and alleviate anxiety, especially when symptoms are severe or persistent.
""Generalized Anxiety Disorder- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Generalized Anxiety Disorder pipeline landscape is provided which includes the disease overview and Generalized Anxiety Disorder treatment guidelines. The assessment part of the report embraces, in depth Generalized Anxiety Disorder commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Generalized Anxiety Disorder collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Generalized Anxiety Disorder R&D. The therapies under development are focused on novel approaches to treat/improve Generalized Anxiety Disorder.
This segment of the Generalized Anxiety Disorder report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Generalized Anxiety Disorder Emerging Drugs
- EXXUA: Fabre-Kramer Pharmaceuticals, Inc.
- MM120: Mind Medicine, Inc.
- ABBV-932: AbbVie
- PSY-05: Psy Therapeutics Inc
Further product details are provided in the report……..
Generalized Anxiety Disorder: Therapeutic Assessment
This segment of the report provides insights about the different Generalized Anxiety Disorder drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Generalized Anxiety Disorder
- There are approx. 12+ key companies which are developing the therapies for Generalized Anxiety Disorder. The companies which have their Generalized Anxiety Disorder drug candidates in the most advanced stage, i.e. Phase III include, Fabre-Kramer Pharmaceuticals, Inc.
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Generalized Anxiety Disorder: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Generalized Anxiety Disorder therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Generalized Anxiety Disorder drugs.
Generalized Anxiety Disorder Report Insights
- Generalized Anxiety Disorder Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Generalized Anxiety Disorder drugs?
- How many Generalized Anxiety Disorder drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Generalized Anxiety Disorder?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Generalized Anxiety Disorder therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Generalized Anxiety Disorder and their status?
- What are the key designations that have been granted to the emerging drugs?
- Fabre-Kramer Pharmaceuticals, Inc.
- Luye Pharma Group Ltd.
- Otsuka Pharmaceutical Co., Ltd.
- Engrail therapeutics
- Intra-Cellular Therapies Inc.
- Incannex
- AbbVie
- GABA Therapeutics, Inc
- EXXUA
- LY03005
- SEP-363856
- ENX-102
- ITI-1284
- PSX-001
- ABBV 932
- GRX-917
Table of Contents
60 Pages
- Introduction
- Executive Summary
- Generalized Anxiety Disorder: Overview
- Introduction
- Causes
- Pathophysiology
- Signs and Symptoms
- Diagnosis
- Treatment
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Generalized Anxiety Disorder– DelveInsight’s Analytical Perspective
- Late Stage Products (Preregistration)
- Comparative Analysis
- EXXUA: Fabre-Kramer Pharmaceuticals, Inc.
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- MM120: Mind Medicine, Inc
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- ABBV-932: AbbVie
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- PSY-05: Psy Therapeutics Inc
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Generalized Anxiety Disorder Key Companies
- Generalized Anxiety Disorder Key Products
- Generalized Anxiety Disorder- Unmet Needs
- Generalized Anxiety Disorder- Market Drivers and Barriers
- Generalized Anxiety Disorder- Future Perspectives and Conclusion
- Generalized Anxiety Disorder Analyst Views
- Generalized Anxiety Disorder Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
